<DOC>
	<DOC>NCT00562237</DOC>
	<brief_summary>Several combinations of H5N1 antigen concentrations and aluminium-hydroxide adjuvant concentrations will be tested for their safety and capacity to induce a specific immune response.</brief_summary>
	<brief_title>Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>being healthy and ≥ 18 and ≤ 49 years of age willing and able to give informed consent having participated in an influenza H5 vaccine trial in the past known to be allergic to any constituent of the vaccine serious adverse reactions to previous (influenza) vaccination currently participating in another clinical trial or having participated in any clinical trial in the month preceding the start of the study using medication that influences the immune system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>adjuvanted pandemic vaccine</keyword>
</DOC>